生命科学资讯

Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum? - Yahoo Finance

Is Roche a Hidden Gem After Its New Immunotherapy Partnerships and Share Price Dip? - Yahoo Finance

Julie Roche named 2025 Fellow of the American Physical Society - Ohio University

Roche pens $1B biobucks deal for Chinese company's respiratory disease bispecific - Fierce Biotech

India breaks into top 10 in Cytiva’s 2025 Global Biopharma Index - BioSpectrum India

Illumina Inc. Q3 Profit Decreases, But Beats Estimates - Nasdaq

Illumina (NASDAQ:ILMN) Beats Q3 Sales Expectations - Yahoo Finance

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 - PR Newswire

Agilent to Announce Fourth-Quarter Fiscal Year 2025 Financial Results on Nov. 24 - Business Wire

Q&A: Large-scale commercial expansion at Lonza’s Stein facility - Fierce Pharma

Insights from 3D Liver Models: Rethinking Fatty Liver Disease with Hormone Correction

10x Genomics (NASDAQ: TXG) launches Chromium Flex enabling 384-sample plate multiplexing - Stock Titan

10x Genomics Launches New Chromium Flex for Single-Cell Research - Contract Pharma

10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research - PR Newswire

Investors in Agilent Technologies (NYSE:A) have seen respectable returns of 41% over the past five years - Yahoo Finance

Thermo Fisher to buy Clario for $8.8bn - Clinical Trials Arena

Thermo Fisher to buy clinical services provider Clario for up to $9.4 billion - Reuters

Thermo Fisher Scientific to accelerate life science breakthroughs with OpenAI - SelectScience

Thermo Fisher to acquire clinical trial data firm Clario for $8.9B - MedTech Dive

Latham & Watkins Advises Clario in US$8.875 Billion Sale to Thermo Fisher Scientific - Latham & Watkins LLP